Expert Review of Vaccines logo Expert Reviews logo

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.

Publisher: Expert Reviews

Volume 7, Number 7, September 2008
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

< previous issue | next issue > | all issues

Special Focus Issue: Cancer Vaccines - Editorial

Cancer vaccines: methods for inducing immunity
pp. 861-862(2)
Authors: Apostolopoulos, Vasso; Weiner, David B; Gong, Jianlin

Special Focus Issue: Cancer Vaccines - News in brief

Special Focus Issue: Cancer Vaccines - Vaccine Profile

PR1 vaccination in myeloid malignancies
pp. 867-875(9)
Author: Rezvani, Katayoun

Special Focus Issue: Cancer Vaccines - Meeting Report

New views on immunopotentiators in modern vaccines
pp. 877-879(3)
Authors: Schijns, Virgil EJC; Brewer, James M

Special Focus Issue: Cancer Vaccines - Perspective

Telomerase as a universal tumor antigen for cancer vaccines
pp. 881-887(7)
Authors: Beatty, Gregory L; Vonderheide, Robert H

Clinical development of MVA-based therapeutic cancer vaccines
pp. 889-893(5)
Authors: Acres, Bruce; Bonnefoy, Jean-Yves

Structural differences among cost-effectiveness models of human papillomavirus vaccines
pp. 895-913(19)
Authors: Insinga, Ralph P; Dasbach, Erik J; Elbasha, Elamin H

Special Focus Issue: Cancer Vaccines - Review

Immunotherapy for HCV infection: next steps
pp. 915-923(9)
Authors: Lang, Krystle; Weiner, David B

Vaccine therapy for renal cancer
pp. 925-935(11)
Author: Amato, Robert J

Melanoma vaccines
pp. 937-949(13)
Authors: Riley, Lee B; Agarwala, Sanjiv S

Strategies used for MUC1 immunotherapy: preclinical studies
pp. 951-962(12)
Authors: Tang, Choon-Kit; Apostolopoulos, Vasso

Strategies used for MUC1 immunotherapy: human clinical studies
pp. 963-975(13)
Authors: Tang, Choon-Kit; Katsara, Maria; Apostolopoulos, Vasso

EGF receptor variant III as a target antigen for tumor immunotherapy
pp. 977-985(9)
Authors: Li, Gordon; Wong, Albert J

Carcinoembryonic antigen as a vaccine target
pp. 987-993(7)
Authors: Wang, Dongmei; Rayani, Shayan; Marshall, John L

Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors
pp. 1005-1018(14)
Authors: Tang, Choon-Kit; Sheng, Kuo-Ching; Apostolopoulos, Vasso; Pietersz, Geoffrey A

Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation
pp. 1019-1030(12)
Authors: Murshid, Ayesha; Gong, Jianlin; Calderwood, Stuart K

Development of multi-epitope vaccines targeting wild-typesequence p53 peptides
pp. 1031-1040(10)
Authors: DeLeo, Albert B; Whiteside, Theresa L

Dendritic cell-based cancer vaccination: quo vadis?
pp. 1041-1053(13)
Authors: Dauer, M; Schnurr, M; Eigler, A

Cell fusion: from hybridoma to dendritic cell-based vaccine
pp. 1055-1068(14)
Authors: Gong, Jianlin; Koido, Shigeo; Calderwood, Stuart K

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
pp. 1069-1084(16)
Authors: Brockstedt, Dirk G; Dubensky, Thomas W

DNA vaccination and gene therapy: optimization and delivery for cancer therapy
pp. 1085-1101(17)
Authors: Bodles-Brakhop, Angela M; Draghia-Akli, Ruxandra

Promising particle-based vaccines in cancer therapy
pp. 1103-1119(17)
Authors: Xiang, Sue D; Scalzo-Inguanti, Karen; Minigo, Gabriela; Park, Anthony; Hardy, Charles L; Plebanski, Magdalena

Special Focus Issue: Cancer Vaccines - Acknowledgements

Acknowledgements
pp. 1129-1129(1)

< previous issue | next issue > | all issues

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A